News
COSMOS HOLDINGS, INC. SIGNS FOR EXCLUSIVE REPRESENTATION AGREEMENT OF COVID-19 DIAGNOSTIC DETECTION KIT FOR GERMANY, ENGLAND, GREECE & CYPRUS
CHICAGO, April 08, 2020 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. ("the Company") (OTCQB: COSM), an international pharmaceutical company, announced today that it has signed a definitive agreement with SunMed Biosciences Limited to be the exclusive representative and distribution agent of a rapid Diagnostic Detection Kit (DDK) into four EU countries: Germany, England, Greece and Cyprus. Specifically, this product is used for qualitative detection of the presence of IgM and/or IgG antibody to SARS-CoV-2, virus that causes COVID-19, in human serum, ...
Cosmos Holdings Engages Exchange Listing To Assist with its NASDAQ-Listing
CHICAGO, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Cosmos Holdings Inc. (OTCQB: COSM) (the “Company”) today announced it has engaged Exchange Listing LLC to assist with the planning and implementation of an up-listing of its common stock to the NASDAQ Capital Markets. “We plan to list our securities on NASDAQ Capital Markets as a next stage in our corporate growth and development,” said Greg Siokas, Chief Executive Officer of Cosmos Holdings. “We believe such a listing will provide a broader trading platform ...
Cosmos Holdings, Inc. Completes $550,000 Debt-to-Equity Conversion at $7.50 Per Share
CHICAGO, June 25, 2019 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“Cosmos” or the “Company”) (OTCQB: COSM), an international pharmaceutical company, announced today it agreed to issue 73,334 shares of common stock to Grigorios Siokas, the Company’s CEO, in exchange for the repayment of $550,000 of loans due to Mr. Siokas. The effective conversion rate is $7.50 per share, 95.8% higher than the $3.83 closing share price of Cosmos on June 24, 2019. Following the conversion of the loans, Cosmos will ...
Cosmos Holdings, Inc. Completes $500,000 Debt-to-Equity Conversion at $7.50 Per Share
CHICAGO, May 31, 2019 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“Cosmos” or the “Company”) (OTCQB: COSM), an international pharmaceutical company, announced today it agreed to issue 66,667 shares of common stock to Grigorios Siokas, the Company’s CEO, in exchange for the repayment of $500,000 of loans due to Mr. Siokas. The effective conversion rate is $7.50 per share, 117% higher than the $3.45 closing share price of Cosmos on May 29, 2019. Following the conversion of the loans, Cosmos will ...
Cosmos Holdings, Inc. Announces Year End 2018 Financial Results
CHICAGO, April 23, 2019 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. ("the Company") (OTCQB: COSM), an international pharmaceutical company, announced its full-year 2018 financial results for the year ended December 31, 2018. 2018 Highlights: - Revenue improved 23.6% to $37 million from $30 million in 2017 - Gross profit increase 23.1% to $2.4 million from $1.96 million in 2017 - Operating expenses decreased by 46.7% year over year. - Repaid the remaining balance of its convertible notes, totaling $5.5 million. - Completed the acquisition of Cosmofarm Ltd., ...
Photo
Steve Carr Managing Director

Join our mailing list to stay up to date.

Cosmos-logo